Xiaofeng Zhang

Prof. Xiaofeng Zhang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2025 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
JZJinglei Zhang
Jinglei Zhang
ZCZhuohuan Chu
Zhuohuan Chu
JLJiawen Li
Jiawen Li
LXLu Xie
Lu Xie
CDCong Ding
Cong Ding
JYJianfeng Yang
Jianfeng Yang
Biliary and pancreatic malignant tumors refer to biliary tract carcinoma (BTC) and pancreatic cancer (PC), among which BTC mainly includes cholangiocarcinoma (CCA) and gallbladder cancer (GBC), and their prognosis is poor because of the lack of effective early diagnostic methods. Although surgical resection is the preferred method for a cure, treatment options are limited for patients with advanced tumors. Therefore, the exploration of other new treatment methods is urgently needed. Currently, metabolic reprogramming is a key mechanism in the process of tumor development and progression and is closely related to cancer cell proliferation, metastasis and drug resistance. As an indispensable part of metabolic reprogramming in tumor cells, amino acid (AA) metabolic reprogramming provides an energy source for tumor cells and participates in regulating the tumor microenvironment (TME). Moreover, as important intrinsic myeloid cells, macrophages play indispensable physiological roles in malignant tumor progression. In the TME, tumor cells can not only induce peripheral immune tolerance by releasing extracellular signals but also compete with tumor-associated macrophages (TAMs) for AAs and release the resulting downstream metabolites into the TME, directly targeting and damaging immune cells and influencing macrophage polarization. Consequently, a more profound understanding of the function of AA metabolic reprogramming in biliopancreatic malignancies and their associated macrophage polarization holds the potential to facilitate the development of effective strategies for early diagnosis, prognostic assessment and targeted therapy in patients with biliopancreatic malignancies. In this paper, we review the impact of AA metabolic reprogramming on the occurrence and development of biliary and pancreatic malignant tumors, summarize the relevant mechanisms of AA metabolic reprogramming on the polarization of TAMs, and provide new therapeutic targets for AA metabolic therapies and immunotherapies for biliary and pancreatic malignant tumors.

9 June 2025 in Functional & Integrative Genomics
Verified
Journal Article
Open access
PDF file
YHYingdong Hou
Yingdong Hou
HXHubin Xia
Hubin Xia
CXChenshan Xu
Chenshan Xu
YYYuhua Yu
Yuhua Yu
CJChenghao Ji
Chenghao Ji
XZXiaofeng Zhang
Xiaofeng Zhang
Emerging evidence has suggested a potential pathological association between early-onset left-sided colorectal cancer (EOLCC) and metabolic syndrome (MetS). However, the underlying genetic and molecular mechanisms remain insufficiently elucidated. This study aimed to identify and characterize key biomarkers associated with the progression and treatment response of MetS-related EOLCC. An in-hospital cohort was utilized to assess the clinical implications of primary tumor location in early-onset colorectal cancer (EOCRC). Differentially expressed genes (DEGs) and weighted gene coexpression network analysis (WGCNA) were employed to identify genes potentially associated with MetS-related EOLCC. Functional enrichment analyses were conducted to explore the underlying mechanisms. Candidate biomarkers were screened using random forest (RF) and support vector machine-recursive feature elimination (SVM-RFE) algorithms. Survival relevance, expression profiles, and diagnostic performance were analyzed to identify key biomarkers. Treatment responses were evaluated, and potential therapeutic compounds were identified through molecular docking. Single-cell RNA sequencing (scRNA-seq) data and in vitro experiments were used to validate gene expression and functional characteristics. The in-hospital cohort revealed a higher proportion of EOLCC among EOCRC patients. Using the edgeR package and WGCNA, we identified coexpressed genes common to both EOLCC and MetS, significantly enriched in pathways associated with stromal remodeling and metabolic regulation. Machine learning algorithms highlighted three candidate biomarkers. Among them, only CD151 was associated with prognosis and advanced disease stage. CD151 was strongly correlated with stromal remodeling and chemoresistance. Additionally, potential therapeutic compounds targeting MetS-related EOLCC were identified via molecular docking. scRNA-seq analysis confirmed the expression and functional patterns of CD151, particularly in tumor cells. The bioinformatics results were further validated through quantitative real-time PCR (qRT-PCR), western blotting, and immunohistochemical (IHC) staining. This study identified CD151 as a key biomarker in MetS-related EOLCC, offering valuable insights into prognosis, tumor biology, and personalized treatment strategies. CD151 may serve as a reference for future research and clinical applications targeting this disease subtype.

27 October 2025 in Human Genomics
Verified
Journal Article
Open access
PDF file
YHYingdong Hou
Yingdong Hou
HXHubin Xia
Hubin Xia
CJChenghao Ji
Chenghao Ji
WKWencheng Kong
Wencheng Kong
YZYifeng Zhou
Yifeng Zhou
XZXiaofeng Zhang
Xiaofeng Zhang
Recent studies have increasingly emphasized the poorer survival outcomes and reduced treatment responses associated with right-sided colon cancer (RCC). However, the underlying molecular mechanisms remain poorly understood. This study aimed to identify and characterize key biomarkers associated with progression and treatment response in patients with RCC. Primary location-related genes (PLGs), including MX1, were identified through weighted gene coexpression network analysis (WGCNA) to construct a primary location signature prognostic risk score (PLriskScore) in the TCGA RCC dataset. The prognostic performance of PLriskScore was validated using four GEO datasets. Tumor microenvironment scores and chemotherapy responses across PLriskScore subgroups were assessed in bulk RNA sequencing datasets. The key target gene was then identified using machine learning algorithms. Its expression and functional roles were examined in single-cell RNA sequencing (scRNA-seq) datasets. Expression patterns were validated by quantitative real-time PCR (qRT-PCR) and immunohistochemical (IHC) staining of clinical samples, while functional characteristics were confirmed using Cell Counting Kit-8 (CCK-8) and transwell migration assays. Seven PLGs (MX1, MLLT6, PEDS1, STK4, TOMM34, SLC35A2, and LZTS3) were used to establish the PLriskScore. A higher PLriskScore was significantly associated with poorer prognosis, advanced TNM stages, and increased stromal scores. Notably, the VEGF pathway was enriched in the high-PLriskScore group. Machine learning algorithms identified MX1 as a novel key target, closely related to chemoresistance and tumor microenvironment dysregulation. scRNA-seq analyses revealed that MX1 was predominantly expressed in epithelial cells and promoted angiogenesis through interactions with endothelial cells via the VEGFA-VEGFR2 pathway. Finally, in vitro experiments demonstrated that MX1 was highly expressed in RCC and enhanced proliferation and migration in two CRC cell lines. A prognostic model based on primary location-related genes was developed to predict prognosis and chemotherapy response in RCC. MX1 was identified as a pivotal target that promotes angiogenesis and chemoresistance, thereby providing a potential therapeutic strategy for patients with RCC.


23 November 2025 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
XDXiulin Dong
Xiulin Dong
WGWeigang Gu
Weigang Gu
SHSijia Hua
Sijia Hua
YGYuhong Gao
Yuhong Gao
KZKun Zhang
Kun Zhang
XZXiaofeng Zhang
Xiaofeng Zhang
Acute pancreatitis (AP) is associated with a high mortality rate, and thereby its therapy is still a challenge. At the molecular level, single-cell RNA sequencing (scRNA-seq) analysis revealed a marked upregulation of pyroptosis (a recently characterized inflammatory programmed cell death pathway) and its key molecular complexes during AP, highlighting the pivotal role of pyroptosis in AP progression. Concurrently, the excessive activation of digestive enzymes within acinar cells triggers pancreatic tissue autodigestion, which exerts profoundly deleterious effects. Thus, in response to these AP pathological characteristics, this study designed a multi-enzyme catalytic system to attenuate pancreatic acinar cell pyroptosis, inactivate pancreatic enzymes, and suppress excessive inflammatory infiltration in pancreatic tissue. Herein, single-atom nanozymes of Co-based SAE (Co-SAE) with inherent antioxidant enzymes surface modified with trypsin activity inhibitor Rhamnetin (Rh) were developed to recover from AP and inhibit the progression of severe acute pancreatitis (SAP). It is found that this formulation (Rh@SAE) conferred effective protection against self-digestion, oxidative stress, inflammatory cell infiltration, tissue damage. Importantly, pyroptotic death of pancreatic acinar cells (PACs) is alleviated as validated by the blockade of GSDMD cleavage, inactivation of caspase 1, and reduction in the release of inflammatory cytokines (IL-1β) and lactate dehydrogenase (LDH). Overall, this work holds significant potential for improving AP outcomes, which opens a new avenue for catalytic therapy in AP.

22 October 2026 in Journal of Biological Chemistry
Verified
Journal Article
Open access
QLQiang Liu
Qiang Liu
CXChenshan Xu
Chenshan Xu
CSChenhao Shi
Chenhao Shi
JLJiawen Li
Jiawen Li
DXDongchao Xu
Dongchao Xu
JYJianfeng Yang
Jianfeng Yang
Ferroptosis is closely linked to increased inflammatory responses and plays a vital role in the development of acute pancreatitis. We investigated how this process contributes to pancreatic injury in AP and examined the interactions between ferroptotic acinar cells and macrophages. Our study profiles the crosstalk mechanisms between ferroptotic acinar cells and macrophages. These findings, derived from human peripheral blood cohorts, were validated in vivo and in vitro. Multi-omics analyses revealed a reduction in pancreatic acinar cells owing to abnormal ferroptosis activation, as confirmed in a cerulein-induced mouse model. Moreover, pretreatment with the ferroptosis inhibitor Lip-1 alleviated acinar cell damage and immune cell infiltration. Results of single-cell RNA analysis indicated that macrophages accumulated near the sites of acinar cell death. Inhibiting ferroptosis significantly decreased macrophage infiltration and M1-like polarization during AP. Mechanistic studies identified Tlr2 as a key gene involved in AP that mediates the interactions between acinar cells and macrophages, promoting inflammation. Tlr2, a receptor for damage-associated molecular patterns linked to AP, was specifically expressed in monocytes/macrophages but not in acinar cells. Genetic knockdown and knockout inhibition did not increase the resistance of acinar cells to ferroptosis in vivo or in vitro. However, inhibiting Tlr2 in macrophages impaired their ability to detect HMGB1 (high mobility group box 1), decreased the stimulation of the NF-κB/NLRP3-signaling pathways, and prevented macrophage polarization to the proinflammatory M1 phenotype. Our results emphasize the role of Tlr2 in the interaction between ferroptotic acinar cells and macrophages, indicating its potential as a therapeutic agent in managing AP.